1,004 results on '"Fornaro, M."'
Search Results
2. POS1099 DIFFICULT-TO-TREAT MANIFESTATIONS OF GRANULOMATOSIS WITH POLYANGIITIS. A EUROPEAN MULTICENTRE STUDY ON SUBGLOTTIC STENOSIS
- Author
-
Moroni, L., primary, Gallina, G. D., additional, Lanzillotta, M., additional, Benanti, G., additional, Cariddi, A., additional, Maggioni, S., additional, Brunetta, E., additional, Conticini, E., additional, Delvino, P., additional, Fagni, F., additional, Fornaro, M., additional, Moroni, G., additional, Peyronel, F., additional, Taille, C., additional, Treppo, E., additional, Matucci-Cerinic, M., additional, and Dagna, L., additional
- Published
- 2024
- Full Text
- View/download PDF
3. AB0238 ASSOCIATION OF Ro52 WITH INTERSTITIAL LUNG DISEASE AND REDUCED SURVIVAL IN DERMATOMYOSITIS
- Author
-
Fornaro, M., primary, Capodiferro, M., additional, Coladonato, L., additional, Sabella, D. V. A., additional, Capuano, A., additional, Lopalco, G., additional, and Iannone, F., additional
- Published
- 2024
- Full Text
- View/download PDF
4. POS0671 PROFILE AND MANAGEMENT OF D2T-RA PATIENTS IN THE ITALIAN GISEA REGISTRY
- Author
-
Fornaro, M., primary, Caporali, R. F., additional, Conti, F., additional, Santo, L., additional, Bazzani, C., additional, Scalvini, A., additional, Cauli, A., additional, Cozzini, F., additional, Ramonda, R., additional, Bugatti, S., additional, Govoni, M., additional, Cantatore, F. P., additional, Gremese, E., additional, Guiducci, S., additional, Atzeni, F., additional, Chimenti, M. S., additional, Rossini, M., additional, Gorla, R., additional, Floris, A., additional, Frediani, B., additional, Biggioggero, M., additional, Foti, R., additional, Congia, M., additional, Parisi, S., additional, Corrado, A., additional, Semeraro, A., additional, Morrone, M., additional, Lomater, C., additional, Mancuso, S., additional, Lapadula, G., additional, Ferraccioli, G., additional, and Iannone, F., additional
- Published
- 2024
- Full Text
- View/download PDF
5. POS0212 UNRAVELING JAK/STAT3 ACTIVATION PATTERNS IN DERMATOMYOSITIS: IMPLICATIONS FOR UNDERSTANDING THE IFN-I SIGNALING PATHWAYS
- Author
-
Del Vescovo, S., primary, Cacciapaglia, F., additional, Fornaro, M., additional, Stano, S., additional, Napoletano, A., additional, Dipietrangelo, G. G., additional, Bizzoca, R., additional, Natuzzi, D., additional, and Iannone, F., additional
- Published
- 2024
- Full Text
- View/download PDF
6. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry
- Author
-
Fornaro, M., Righetti, G., Abbruzzese, A., Lopalco, G., Cacciapaglia, F., Anelli, M. G., Venerito, V., and Iannone, F.
- Published
- 2021
- Full Text
- View/download PDF
7. Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression
- Author
-
Fornaro, M., Novello, S., Fusco, A., Anastasia, A., De Prisco, M., Mondin, A.M., Mosca, P., Iasevoli, F., and de Bartolomeis, A.
- Published
- 2021
- Full Text
- View/download PDF
8. Psychopharmacology of eating disorders: Systematic review and meta-analysis of randomized controlled trials
- Author
-
Fornaro, M, Mondin, A, Billeci, M, Fusco, A, De Prisco, M, Caiazza, C, Micanti, F, Calati, R, Carvalho, A, de Bartolomeis, A, Fornaro M., Mondin A. M., Billeci M., Fusco A., De Prisco M., Caiazza C., Micanti F., Calati R., Carvalho A. F., de Bartolomeis A., Fornaro, M, Mondin, A, Billeci, M, Fusco, A, De Prisco, M, Caiazza, C, Micanti, F, Calati, R, Carvalho, A, de Bartolomeis, A, Fornaro M., Mondin A. M., Billeci M., Fusco A., De Prisco M., Caiazza C., Micanti F., Calati R., Carvalho A. F., and de Bartolomeis A.
- Abstract
Background: The concurrent assessment of weight and affective psychopathology outcomes relevant to the psychopharmacology of major eating disorders (EDs), namely anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED), warrants systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: PubMed, Scopus, and ClinicalTrials.gov were inquired from inception through August 31st, 2022, for RCTs documenting any psychopharmacological intervention for EDs diagnosed according to validated criteria and reporting weight and psychopathology changes. Adopted keywords were: “anorexia nervosa,” “bulimia nervosa,” “binge eating disorder,” “antidepressant,” “antipsychotic,” and “mood stabilizer.” No language restriction applied. Results: 5122 records were identified, and 203 full-texts were reviewed. Sixty-two studies entered the qualitative synthesis (AN = 22, BN = 23, BED = 17), of which 22 entered the meta-analysis (AN = 9, BN = 10, BED = 3). Concerning BMI increase in AN, olanzapine outperformed placebo (Hedges'g = 0.283, 95%C·I. = 0.051–0.515, I2 = 0 %; p =.017), whereas fluoxetine failed (Hedges'g = 0.351, 95%C.I. = −0.248 to 0.95, I2 = 63.37 %; p =.251). Fluoxetine not significantly changed weight (Hedges'g = 0.147, 95%C.I. = −0.157–0.451, I2 = 0 %; p =.343), reducing binging (Hedges'g = 0.203, 95%C.I. = 0.007–0.399, I2 = 0 %; p =.042), and purging episodes (Hedges'g = 0.328, 95%C.I. = −0.061–0.717, I2 = 58.97 %; p =.099) in BN. Lisdexamfetamine reduced weight (Hedges'g = 0.259, 95%C.I. = 0.071–0.446, I2 = 0 %; p =.007) and binging (Hedges'g = 0.571, 95%C.I. = 0.282–0.860, I2 = 53.84 %; p <.001) in BED. Limitations: Small sample size, short duration, and lack of reliable operational definitions affect most of the included sponsored RCTs. Conclusions: The efficacy of different drugs varies across different EDs, warranting additional primary studies recording broad psychopathological and cardiometabolic outcomes besides weight, es
- Published
- 2023
9. Suicide and homicide before and during the COVID-19 pandemic in Milan, Italy
- Author
-
Calati, R, Gentile, G, Fornaro, M, Madeddu, F, Tambuzzi, S, Zoja, R, Calati R., Gentile G., Fornaro M., Madeddu F., Tambuzzi S., Zoja R., Calati, R, Gentile, G, Fornaro, M, Madeddu, F, Tambuzzi, S, Zoja, R, Calati R., Gentile G., Fornaro M., Madeddu F., Tambuzzi S., and Zoja R.
- Abstract
Background: The COVID-19 pandemic has been postulated to account for inflated rates of either suicides or homicides. Nonetheless, results are discordant, in particular concerning suicide. We aimed to perform a retrospective analysis of suicides and homicides in the region of Lombardy, Northern Italy (districts of Milan and Monza Brianza), the Italian region most seriously impacted by the pandemic outbreak. Methods: Data were collected during the autopsies performed at the Institute of Forensic Medicine in Milan. We presented suicides and homicides in the years 2015-2021 and compared the year 2021 to 2019, a pre-COVID-19 year. Results: Data may allow us to cautiously hypothesize a normalization of trends ("regression" to the mean effect) as time passes from the COVID-19 outbreak. Limitations: Limited number of events, in particular, homicides. Conclusions: Recording historical reports from the same region is warranted besides the comparisons across different countries.
- Published
- 2023
10. Contributors
- Author
-
Ahearn, Eileen, primary, Al Mugaddam, Fadwa, additional, Amore, M., additional, Anastasia, A., additional, Andrews, Taylor, additional, Anmella, Gerard, additional, Arnone, Danilo, additional, Ashdown-Franks, Garcia, additional, Aziz, Karim Abdel, additional, Barichello, Tatiana, additional, Bauer, Moisés E., additional, Baune, Bernhard T., additional, Bellani, Marcella, additional, Bellivier, Frank, additional, Benedetti, Francesco, additional, Benevenuto, Deborah, additional, Bock, Nicholas A., additional, Bora, Emre, additional, Brambilla, Paolo, additional, Brunoni, Andre Russowsky, additional, Calabrese, Joseph R., additional, Camino, Sebastián, additional, Cararo, José H., additional, Carvalho, Andre Ferrer, additional, Ceylan, Deniz, additional, Chakrabarty, Trisha, additional, Chen, Peijun, additional, Cipriani, N., additional, Collodel, Allan, additional, Colombo, C., additional, Dallaspezia, Sara, additional, Del Fabro, Lorenzo, additional, DelBello, Melissa P., additional, Delvecchio, Giuseppe, additional, Doifode, Tejaswini, additional, DuBow, Anaïs, additional, Etain, Bruno, additional, Farrow, Jenni E., additional, Fernandes, Brisa S., additional, Fornaro, M., additional, Fregna, L., additional, Frey, Benicio N., additional, Fries, Gabriel R., additional, Fusco, A., additional, Gao, Keming, additional, Garza, Jacob C., additional, Gava, Fernanda F., additional, Generoso, Jaqueline S., additional, Giménez, Anna, additional, Giridharan, Vijayasree, additional, Goldstein, Benjamin I., additional, Gomes-da-Costa, Susana, additional, Grande, Iria, additional, Haggarty, Stephen J., additional, Hennion, Vincent, additional, Husain, Muhammad I., additional, Juster, Robert-Paul, additional, Kato, Tadafumi, additional, Keramatian, Kamyar, additional, Kloiber, Stefan, additional, Lima, Camila Nayane de Carvalho, additional, Locatelli, M., additional, Machado-Vieira, Rodrigo, additional, Melun, Jean-Pierre, additional, Meyer, Jeffrey H., additional, Mio, Megan, additional, Murru, Andrea, additional, Nery, Fabiano G., additional, Özerdem, Ayşegül, additional, Pacchiarotti, Isabella, additional, Pariante, Carmine Maria, additional, Patino, Luis Rodrigo, additional, Perlis, Roy H., additional, Pilieci, Christopher, additional, Pinjari, Omar F., additional, Pink, Omar, additional, Pinto, Jairo Vinícius, additional, Pisanu, Claudia, additional, Quevedo, Joao, additional, Rosenblat, Joshua D., additional, Sabiston, Catherine M., additional, Sajatovic, Martha, additional, Salagre, Estela, additional, de Sampaio Pereira Júnior, Bernardo, additional, Saraf, Gayatri, additional, Scaini, Giselli, additional, Seghi, F., additional, Sehmbi, Manpreet, additional, Serafini, G., additional, Sforzini, Luca, additional, Shahani, Lokesh, additional, Singhal, Gaurav, additional, Squassina, Alessio, additional, Stertz, Laura, additional, Teixeira, Antonio L., additional, Trinetti, Jessica, additional, Valvassori, Samira S., additional, Vázquez, Gustavo, additional, Vieta, Eduard, additional, Walss-Bass, Consuelo, additional, Wieck, Andrea, additional, Yatham, Lakshmi N., additional, and Zhao, Wen-Ning, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Is there a biosignature for lithium response in bipolar disorder? Evidence and implications
- Author
-
Fornaro, M., primary, Anastasia, A., additional, Fusco, A., additional, and Carvalho, Andre Ferrer, additional
- Published
- 2021
- Full Text
- View/download PDF
12. Scale effects in the ‘micro-scale’ rock mechanics problems
- Author
-
Mancini, R., primary, Cardu, M., additional, Fornaro, M., additional, and Linares, M., additional
- Published
- 2020
- Full Text
- View/download PDF
13. Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients
- Author
-
Fornaro, M., Iasevoli, F., Novello, S., Fusco, A., Anastasia, A., De Berardis, D., Valchera, A., and de Bartolomeis, A.
- Published
- 2018
- Full Text
- View/download PDF
14. Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity
- Author
-
Fornaro, M, primary, Girolamo, F, additional, Cacciapaglia, F, additional, Carabellese, G, additional, Bizzoca, R, additional, Scioscia, C, additional, Coladonato, L, additional, Lopalco, G, additional, Ruggieri, M, additional, Mastrapasqua, M, additional, Fari, G, additional, D’Abbicco, D, additional, and Iannone, F, additional
- Published
- 2023
- Full Text
- View/download PDF
15. AB0775 EFFECTIVENESS AND SAFETY OF NON-MEDICAL SWITCH FROM RITUXIMAB ORIGINATOR TO AND AMONG BIOSIMILARS IN SMALL VESSEL VASCULITIDES PATIENTS: REAL WORLD DATA FROM A RETROSPECTIVE MONOCENTRIC STUDY
- Author
-
Stano, S., primary, Coladonato, L., additional, Capuano, A., additional, Lavista, M., additional, Spedicato, V., additional, Fornaro, M., additional, Iannone, F., additional, and Cacciapaglia, F., additional
- Published
- 2023
- Full Text
- View/download PDF
16. POS1216 MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY)
- Author
-
Fornaro, M., primary, Venerito, V., additional, Iannone, F., additional, Ravichandran, N., additional, Nikiphorou, E., additional, Joshi, M., additional, Tan, A. L., additional, Saha, S., additional, Katsuyuki Shinjo, S., additional, Agarwal, V., additional, Ziade, N., additional, Velikova, T., additional, Jagtap, K., additional, Milchert, M., additional, Parodis, I., additional, Gracia-Ramos, A. E., additional, Cavagna, L., additional, Kuwana, M., additional, Knitza, J., additional, Makol, A., additional, Dzifa, D., additional, Toro Gutierrez, C. E., additional, Vinicio Caballero, C., additional, Distler, O., additional, Day, J., additional, Study, C., additional, Chinoy, H., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
17. POS1388-HPR RELATIONSHIP BETWEEN CENTRAL SENSITIZATION AND PSYCHOLOGICAL FACTORS IN RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL, MULTICENTER STUDY
- Author
-
Spinelli, F. R., primary, Quartuccio, L., additional, Farah, S., additional, Bazzani, C., additional, Nacci, F., additional, Fornaro, M., additional, Iacono, D., additional, Baldi, C., additional, Perniola, S., additional, Longhino, S., additional, and Salaffi, F., additional
- Published
- 2023
- Full Text
- View/download PDF
18. POS0852 REAL LIFE DATA OF FILGOTINIB IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM ITALIAN GISEA REGISTRY
- Author
-
Fornaro, M., primary, Caporali, R., additional, Montecucco, C., additional, Cauli, A., additional, Conti, F., additional, Chimenti, M. S., additional, Gorla, R., additional, Atzeni, F., additional, Semeraro, A., additional, Gremese, E., additional, Sebastiani, M., additional, Govoni, M., additional, Cantatore, F. P., additional, Santo, L., additional, Frediani, B., additional, Lapadula, G., additional, Ferraccioli, G., additional, and Iannone, F., additional
- Published
- 2023
- Full Text
- View/download PDF
19. POS0857 EFFECTIVENESS AND SAFETY OF BIOLOGIC AND TARGET SYNTHETIC DRUGS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN THE ERA OF JAK INHIBITORS: A REAL-LIFE STUDY FROM BIOPURE REGISTRY
- Author
-
Fornaro, M., primary, Santo, L., additional, Bucci, R. N. G., additional, Semeraro, A., additional, Carlino, G., additional, Quarta, L., additional, D’onofrio, F., additional, Lazzari, A., additional, Serafino, L., additional, Marsico, A., additional, Zuccaro, C., additional, Falappone, P. C. F., additional, Mazzotta, D., additional, Cantatore, F. P., additional, and Iannone, F., additional
- Published
- 2023
- Full Text
- View/download PDF
20. POS0124 SURVIVAL ANALYSIS IN CONNECTIVE TISSUE DISEASES WITH INTERSTITIAL LUNG DISEASE COMPARED TO IDIOPATHIC PULMONARY FIBROSIS: MULTICENTRE ITALIAN STUDY
- Author
-
Fornaro, M., primary, Cacciapaglia, F., additional, Giotta, M., additional, Zanframundo, G., additional, Lazzaroni, M. G., additional, Bartoletti, A., additional, Pedretti, E., additional, Sambataro, G., additional, Orlandi, M., additional, De Pace, C. C., additional, Colella, S., additional, Lacedonia, D., additional, Vanchieri, C., additional, Airo’, P., additional, Cavagna, L., additional, Guiducci, S., additional, and Iannone, F., additional
- Published
- 2023
- Full Text
- View/download PDF
21. OP0012-HPR CENTRAL SENSITIZATION HAS MAJOR IMPACT ON DISEASE ACTIVITY, FUNCTIONAL DISABILITY AND FRAILTY IN PATIENTS WITH RA
- Author
-
Quartuccio, L., primary, Spinelli, F. R., additional, Farah, S., additional, Bazzani, C., additional, Nacci, F., additional, Fornaro, M., additional, Iacono, D., additional, Baldi, C., additional, Perniola, S., additional, Longhino, S., additional, and Salaffi, F., additional
- Published
- 2023
- Full Text
- View/download PDF
22. POS0992-HPR THE EFFECT OF CENTRAL SENSITIZATION ON DISEASE SEVERITY LEVELS AND PRESENTEEISM-RELATED PRODUCTIVITY LOSS IN FEMALE WORKERS WITH RA
- Author
-
Farah, S., primary, Spinelli, F. R., additional, Quartuccio, L., additional, Bazzani, C., additional, Nacci, F., additional, Fornaro, M., additional, Iacono, D., additional, Baldi, C., additional, Perniola, S., additional, Longhino, S., additional, and Salaffi, F., additional
- Published
- 2023
- Full Text
- View/download PDF
23. POS0880 COMPARATIVE DISEASE BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: DATA FROM COVAD PATIENT-REPORTED E-SURVEY
- Author
-
Venerito, V., primary, Fornaro, M., additional, Iannone, F., additional, Cavagna, L., additional, Kuwana, M., additional, Agarwal, V., additional, Ravichandran, N., additional, Day, J., additional, Joshi, M., additional, Saha, S., additional, Shaharir, S. S., additional, Katchamart, W., additional, Goo, P. A., additional, Traboco, L., additional, Chen, Y. M., additional, Sen, P., additional, Lilleker, J. B., additional, Nune, A., additional, Pauling, J., additional, Wincup, C., additional, Tan, A. L., additional, Ziade, N., additional, Milchert, M., additional, Gracia-Ramos, A. E., additional, Vinicio Caballero, C., additional, Study, C., additional, Aggarwal, R., additional, and Gupta, L., additional
- Published
- 2023
- Full Text
- View/download PDF
24. AB0241 PATIENTS WITH RHEUMATOID ARTHRITIS AND RHEUMATOLOGISTS AGED ≤ 40 YEARS HAVE DIFFERENT PRIORITIES AND PERSPECTIVES ON DISEASE MANAGEMENT: THE ITALIAN SOCIETY FOR RHEUMATOLOGY YOUNG (SIRYOUNG) COMMISSION SURVEY
- Author
-
Alivernini, S., primary, Perniola, S., additional, Bardelli, M., additional, Batticciotto, A., additional, Bozzalla Cassione, E., additional, Crisafulli, F., additional, Gentileschi, S., additional, Luciano, N., additional, Mauro, D., additional, Orlandi, M., additional, Sciacca, S., additional, Ortolan, A., additional, Todoerti, M., additional, Fornaro, M., additional, Andreoli, L., additional, and Chighizola, C., additional
- Published
- 2023
- Full Text
- View/download PDF
25. Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early rheumatoid arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients wiTh Rheumatoid Arthritis (the MITRA study). A cohort study of the Italian Society for Rheumatology
- Author
-
Fornaro, M, Benaglio, F, Montecucco, C, Raffeiner, B, Di Franco, M, Iannuccelli, C, Conigliaro, P, Lomater, C, Govoni, M, Silvagni, E, Zanetti, A, Parisi, S, Carrara, G, Scire, C, Caporali, R, Iannone, F, Fornaro M., Benaglio F., Montecucco C., Raffeiner B., Di Franco M., Iannuccelli C., Conigliaro P., Lomater C., Govoni M., Silvagni E., Zanetti A., Parisi S., Carrara G., Scire C. A., Caporali R., Iannone F., Fornaro, M, Benaglio, F, Montecucco, C, Raffeiner, B, Di Franco, M, Iannuccelli, C, Conigliaro, P, Lomater, C, Govoni, M, Silvagni, E, Zanetti, A, Parisi, S, Carrara, G, Scire, C, Caporali, R, Iannone, F, Fornaro M., Benaglio F., Montecucco C., Raffeiner B., Di Franco M., Iannuccelli C., Conigliaro P., Lomater C., Govoni M., Silvagni E., Zanetti A., Parisi S., Carrara G., Scire C. A., Caporali R., and Iannone F.
- Abstract
Objective The aim of this study was to assess the real-life adherence of Italian rheumatologist to the 2013 EULAR recommendations and treatment outcome in rheumatoid arthritis (RA) patients who started a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD). Methods The MITRA study is an Italian multicentre observational cohort focused on treatment naïve RA patients with early diagnosis recruited in an 18-month period starting from 2015. The data related to treatment with csDMARDs during the following 12 months follow-up were presented in this paper. Results Two-hundred and fifty-nine RA patients from MITRA cohort who had a follow-up visit and started a csDMARD were included in the prospective analysis. Methotrexate was started as first conventional DMARD in 224 (86.4%) patients. During the first year after starting conventional DMARDs, 175 (67.6%) RA patients reached the pre-specified target, which was DAS28 remission (<2.6) for 112 (43.2%) patients and LDA (<3.2) for 63 (24.3%) patients. Factors that negatively impacted the target achievement were fibromyalgia (HR: 0.2 [0.05-0.81]), HAQ-DI (HR: 0.72 [0.56-0.93]) and ESR (HR: 0.99 [0.99-1]). Globally, 33 (12.7%) patients started a biologic DMARD, while 61 out of 84 (72.6%) patients who had never reached the target remained on conventional DMARD. One-hundred and ninety-three adverse events (AEs) were recorded, the majority classified as mild (91 cases, 51%). Conclusion A high proportion of RA patients achieved the target during the first-year follow-up. However, a considerable portion of RA patients did not start a biological drug although the target was never reached. AEs remain frequent with conventional DMARDs, but the majority were mild.
- Published
- 2022
26. Cancer diagnosis and suicide outcomes: prevalence and risk meta-analysis
- Author
-
Peviani, G, Casu, D, Mansi, W, De Prisco, M, Madeddu, F, López-Castroman, J, Fornaro, M, Calati, R, Peviani G, Casu D, Mansi W, De Prisco M, Madeddu F, López-Castroman J, Fornaro M, Calati R, Peviani, G, Casu, D, Mansi, W, De Prisco, M, Madeddu, F, López-Castroman, J, Fornaro, M, Calati, R, Peviani G, Casu D, Mansi W, De Prisco M, Madeddu F, López-Castroman J, Fornaro M, and Calati R
- Published
- 2022
27. The association between self-esteem and suicidal risk: a meta-analysis
- Author
-
Lippo, F, Madeddu, F, Fornaro, M, Calati, R, Lippo F, Madeddu F, Fornaro M, Calati R, Lippo, F, Madeddu, F, Fornaro, M, Calati, R, Lippo F, Madeddu F, Fornaro M, and Calati R
- Published
- 2022
28. Physical pain-suicidality association in all ages: a complete and updated meta-analysis
- Author
-
Rignanese, M, Salmè, E, De Filippi, M, Madeddu, F, De Prisco, M, Fornaro, M, Calati, R, Rignanese M, Salmè E, De Filippi M, Madeddu F, De Prisco M, Fornaro M, Calati R, Rignanese, M, Salmè, E, De Filippi, M, Madeddu, F, De Prisco, M, Fornaro, M, Calati, R, Rignanese M, Salmè E, De Filippi M, Madeddu F, De Prisco M, Fornaro M, and Calati R
- Published
- 2022
29. Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials
- Author
-
Fornaro, M, Dragioti, E, De Prisco, M, Billeci, M, Mondin, A, Calati, R, Smith, L, Hatcher, S, Kaluzienski, M, Fiedorowicz, J, Solmi, M, de Bartolomeis, A, Carvalho, A, Fornaro M, Dragioti E, De Prisco M, Billeci M, Mondin AM, Calati R, Smith L, Hatcher S, Kaluzienski M, Fiedorowicz JG, Solmi M, de Bartolomeis A, Carvalho AF, Fornaro, M, Dragioti, E, De Prisco, M, Billeci, M, Mondin, A, Calati, R, Smith, L, Hatcher, S, Kaluzienski, M, Fiedorowicz, J, Solmi, M, de Bartolomeis, A, Carvalho, A, Fornaro M, Dragioti E, De Prisco M, Billeci M, Mondin AM, Calati R, Smith L, Hatcher S, Kaluzienski M, Fiedorowicz JG, Solmi M, de Bartolomeis A, and Carvalho AF
- Abstract
Background: Homelessness has been associated with multiple detrimental health outcomes across observational studies. However, relatively few randomized controlled trials (RCTs) have been conducted on people who experience homelessness (PEH). Thus, this umbrella review ranked the credibility of evidence derived from systematic reviews (SRs) and meta-analyses (MAs) of observational studies investigating the associations between homelessness and any health outcome as well as RCTs targeting health needs in this population. Methods: Several databases were systematically searched from inception through April 28, 2021. Any SR and/or MA reporting quantitative data and providing a control group were eligible for inclusion. The credibility of the evidence derived from observational studies was appraised by considering the significance level of the association and the largest study, the degree of heterogeneity, the presence of small-study effects as well as excess significance bias. The credibility of evidence was then ranked in five classes. For SRs and/or MAs of RCTs, we considered the level of significance and whether the prediction interval crossed the null. The AMSTAR-2 and AMSTAR-plus instruments were adopted to further assess the methodological quality of SRs and/or MAs. The Newcastle-Ottawa Scale (NOS) was employed to further appraise the methodological quality of prospective cohort studies only; a sensitivity analysis limited to higher quality studies was conducted. Results: Out of 1549 references, 8 MAs and 2 SRs were included. Among those considering observational studies, 23 unique associations were appraised. Twelve of them were statistically significant at the p≤0.005 level. Included cases had worst health-related outcomes than controls, but only two associations reached a priori-defined criteria for convincing (class I) evidence namely hospitalization due to any cause among PEH diagnosed with HIV infection, and the occurrence of falls within the past year among
- Published
- 2022
30. Suicide numbers during the first 9-15 months of the COVID-19 pandemic compared with pre-existing trends: An interrupted time series analysis in 33 countries
- Author
-
Pirkis, J, Gunnell, D, Shin, S, Del Pozo-Banos, M, Arya, V, Aguilar, P, Appleby, L, Arafat, S, Arensman, E, Ayuso-Mateos, J, Balhara, Y, Bantjes, J, Baran, A, Behera, C, Bertolote, J, Borges, G, Bray, M, Brečić, P, Caine, E, Calati, R, Carli, V, Castelpietra, G, Chan, L, Chang, S, Colchester, D, Coss-Guzmán, M, Crompton, D, Ćurković, M, Dandona, R, De Jaegere, E, De Leo, D, Deisenhammer, E, Dwyer, J, Erlangsen, A, Faust, J, Fornaro, M, Fortune, S, Garrett, A, Gentile, G, Gerstner, R, Gilissen, R, Gould, M, Gupta, S, Hawton, K, Holz, F, Kamenshchikov, I, Kapur, N, Kasal, A, Khan, M, Kirtley, O, Knipe, D, Kõlves, K, Kölzer, S, Krivda, H, Leske, S, Madeddu, F, Marshall, A, Memon, A, Mittendorfer-Rutz, E, Nestadt, P, Neznanov, N, Niederkrotenthaler, T, Nielsen, E, Nordentoft, M, Oberlerchner, H, O'Connor, R, Papsdorf, R, Partonen, T, Phillips, M, Platt, S, Portzky, G, Psota, G, Qin, P, Radeloff, D, Reif, A, Reif-Leonhard, C, Rezaeian, M, Román-Vázquez, N, Roskar, S, Rozanov, V, Sara, G, Scavacini, K, Schneider, B, Semenova, N, Sinyor, M, Tambuzzi, S, Townsend, E, Ueda, M, Wasserman, D, Webb, R, Winkler, P, Yip, P, Zalsman, G, Zoja, R, John, A, Spittal, M, Pirkis J, Gunnell D, Shin S, Del Pozo-Banos M, Arya V, Aguilar PA, Appleby L, Arafat SMY, Arensman E, Ayuso-Mateos JL, Balhara YPS, Bantjes J, Baran A, Behera C, Bertolote J, Borges G, Bray M, Brečić P, Caine E, Calati R, Carli V, Castelpietra G, Chan LF, Chang SS, Colchester D, Coss-Guzmán M, Crompton D, Ćurković M, Dandona R, De Jaegere E, De Leo D, Deisenhammer EA, Dwyer J, Erlangsen A, Faust JS, Fornaro M, Fortune S, Garrett A, Gentile G, Gerstner R, Gilissen R, Gould M, Gupta SK, Hawton K, Holz F, Kamenshchikov I, Kapur N, Kasal A, Khan M, Kirtley OJ, Knipe D, Kõlves K, Kölzer SC, Krivda H, Leske S, Madeddu F, Marshall A, Memon A, Mittendorfer-Rutz E, Nestadt P, Neznanov N, Niederkrotenthaler T, Nielsen E, Nordentoft M, Oberlerchner H, O'Connor RC, Papsdorf R, Partonen T, Phillips MR, Platt S, Portzky G, Psota G, Qin P, Radeloff D, Reif A, Reif-Leonhard C, Rezaeian M, Román-Vázquez N, Roskar S, Rozanov V, Sara G, Scavacini K, Schneider B, Semenova N, Sinyor M, Tambuzzi S, Townsend E, Ueda M, Wasserman D, Webb RT, Winkler P, Yip PSF, Zalsman G, Zoja R, John A, Spittal MJ, Pirkis, J, Gunnell, D, Shin, S, Del Pozo-Banos, M, Arya, V, Aguilar, P, Appleby, L, Arafat, S, Arensman, E, Ayuso-Mateos, J, Balhara, Y, Bantjes, J, Baran, A, Behera, C, Bertolote, J, Borges, G, Bray, M, Brečić, P, Caine, E, Calati, R, Carli, V, Castelpietra, G, Chan, L, Chang, S, Colchester, D, Coss-Guzmán, M, Crompton, D, Ćurković, M, Dandona, R, De Jaegere, E, De Leo, D, Deisenhammer, E, Dwyer, J, Erlangsen, A, Faust, J, Fornaro, M, Fortune, S, Garrett, A, Gentile, G, Gerstner, R, Gilissen, R, Gould, M, Gupta, S, Hawton, K, Holz, F, Kamenshchikov, I, Kapur, N, Kasal, A, Khan, M, Kirtley, O, Knipe, D, Kõlves, K, Kölzer, S, Krivda, H, Leske, S, Madeddu, F, Marshall, A, Memon, A, Mittendorfer-Rutz, E, Nestadt, P, Neznanov, N, Niederkrotenthaler, T, Nielsen, E, Nordentoft, M, Oberlerchner, H, O'Connor, R, Papsdorf, R, Partonen, T, Phillips, M, Platt, S, Portzky, G, Psota, G, Qin, P, Radeloff, D, Reif, A, Reif-Leonhard, C, Rezaeian, M, Román-Vázquez, N, Roskar, S, Rozanov, V, Sara, G, Scavacini, K, Schneider, B, Semenova, N, Sinyor, M, Tambuzzi, S, Townsend, E, Ueda, M, Wasserman, D, Webb, R, Winkler, P, Yip, P, Zalsman, G, Zoja, R, John, A, Spittal, M, Pirkis J, Gunnell D, Shin S, Del Pozo-Banos M, Arya V, Aguilar PA, Appleby L, Arafat SMY, Arensman E, Ayuso-Mateos JL, Balhara YPS, Bantjes J, Baran A, Behera C, Bertolote J, Borges G, Bray M, Brečić P, Caine E, Calati R, Carli V, Castelpietra G, Chan LF, Chang SS, Colchester D, Coss-Guzmán M, Crompton D, Ćurković M, Dandona R, De Jaegere E, De Leo D, Deisenhammer EA, Dwyer J, Erlangsen A, Faust JS, Fornaro M, Fortune S, Garrett A, Gentile G, Gerstner R, Gilissen R, Gould M, Gupta SK, Hawton K, Holz F, Kamenshchikov I, Kapur N, Kasal A, Khan M, Kirtley OJ, Knipe D, Kõlves K, Kölzer SC, Krivda H, Leske S, Madeddu F, Marshall A, Memon A, Mittendorfer-Rutz E, Nestadt P, Neznanov N, Niederkrotenthaler T, Nielsen E, Nordentoft M, Oberlerchner H, O'Connor RC, Papsdorf R, Partonen T, Phillips MR, Platt S, Portzky G, Psota G, Qin P, Radeloff D, Reif A, Reif-Leonhard C, Rezaeian M, Román-Vázquez N, Roskar S, Rozanov V, Sara G, Scavacini K, Schneider B, Semenova N, Sinyor M, Tambuzzi S, Townsend E, Ueda M, Wasserman D, Webb RT, Winkler P, Yip PSF, Zalsman G, Zoja R, John A, and Spittal MJ
- Abstract
Background: Predicted increases in suicide were not generally observed in the early months of the COVID-19 pandemic. However, the picture may be changing and patterns might vary across demographic groups. We aimed to provide a timely, granular picture of the pandemic's impact on suicides globally. Methods: We identified suicide data from official public-sector sources for countries/areas-within-countries, searching websites and academic literature and contacting data custodians and authors as necessary. We sent our first data request on 22nd June 2021 and stopped collecting data on 31st October 2021. We used interrupted time series (ITS) analyses to model the association between the pandemic's emergence and total suicides and suicides by sex-, age- and sex-by-age in each country/area-within-country. We compared the observed and expected numbers of suicides in the pandemic's first nine and first 10-15 months and used meta-regression to explore sources of variation. Findings: We sourced data from 33 countries (24 high-income, six upper-middle-income, three lower-middle-income; 25 with whole-country data, 12 with data for area(s)-within-the-country, four with both). There was no evidence of greater-than-expected numbers of suicides in the majority of countries/areas-within-countries in any analysis; more commonly, there was evidence of lower-than-expected numbers. Certain sex, age and sex-by-age groups stood out as potentially concerning, but these were not consistent across countries/areas-within-countries. In the meta-regression, different patterns were not explained by countries’ COVID-19 mortality rate, stringency of public health response, economic support level, or presence of a national suicide prevention strategy. Nor were they explained by countries’ income level, although the meta-regression only included data from high-income and upper-middle-income countries, and there were suggestions from the ITS analyses that lower-middle-income countries fared less well
- Published
- 2022
31. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies
- Author
-
Cavagna, L, Meloni, F, Meyer, A, Sambataro, G, Belliato, M, De Langhe, E, Cavazzana, I, Pipitone, N, Triantafyllias, K, Mosca, M, Barsotti, S, Zampogna, G, Biglia, A, Emmi, G, De Visser, M, Van Der Kooi, A, Parronchi, P, Hirschi, S, da Silva, J, Scire, C, Furini, F, Giannini, M, Martinez Gonzalez, O, Damian, L, Piette, Y, Smith, V, Mera-Valera, A, Bachiller-Corral, J, Cabezas Rodriguez, I, Brandy-Garcia, A, Maurier, F, Perrin, J, Gonzalez-Moreno, J, Drott, U, Delbruck, C, Schwarting, A, Arrigoni, E, Sebastiani, G, Iuliano, A, Nannini, C, Quartuccio, L, Rodriguez Cambron, A, Blazquez Canamero, M, Villa Blanco, I, Cagnotto, G, Pesci, A, Luppi, F, Dei, G, Romero Bueno, F, Franceschini, F, Chiapparoli, I, Zanframundo, G, Lettieri, S, De Stefano, L, Cutolo, M, Mathieu, A, Piga, M, Prieto-Gonzalez, S, Moraes-Fontes, M, Fonseca, J, Jovani, V, Riccieri, V, Santaniello, A, Montfort, S, Bilocca, D, Erre, G, Bartoloni, E, Gerli, R, Monti, M, Lorenz, H, Sambataro, D, Bellando Randone, S, Schneider, U, Valenzuela, C, Lopez-Mejias, R, Cifrian, J, Mejia, M, Gonzalez Perez, M, Wendel, S, Fornaro, M, De Luca, G, Orsolini, G, Rossini, M, Dieude, P, Knitza, J, Castaneda, S, Voll, R, Rojas-Serrano, J, Valentini, A, Vancheri, C, Matucci-Cerinic, M, Feist, E, Codullo, V, Iannone, F, Distler, J, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Meloni F., Meyer A., Sambataro G., Belliato M., De Langhe E., Cavazzana I., Pipitone N., Triantafyllias K., Mosca M., Barsotti S., Zampogna G., Biglia A., Emmi G., De Visser M., Van Der Kooi A., Parronchi P., Hirschi S., da Silva J. A. P., Scire C. A., Furini F., Giannini M., Martinez Gonzalez O., Damian L., Piette Y., Smith V., Mera-Valera A., Bachiller-Corral J., Cabezas Rodriguez I., Brandy-Garcia A. M., Maurier F., Perrin J., Gonzalez-Moreno J., Drott U., Delbruck C., Schwarting A., Arrigoni E., Sebastiani G. D., Iuliano A., Nannini C., Quartuccio L., Rodriguez Cambron A. B., Blazquez Canamero M. A., Villa Blanco I., Cagnotto G., Pesci A., Luppi F., Dei G., Romero Bueno F. I., Franceschini F., Chiapparoli I., Zanframundo G., Lettieri S., De Stefano L., Cutolo M., Mathieu A., Piga M., Prieto-Gonzalez S., Moraes-Fontes M. F., Fonseca J. E., Jovani V., Riccieri V., Santaniello A., Montfort S., Bilocca D., Erre G. L., Bartoloni E., Gerli R., Monti M. C., Lorenz H. M., Sambataro D., Bellando Randone S., Schneider U., Valenzuela C., Lopez-Mejias R., Cifrian J., Mejia M., Gonzalez Perez M. -I., Wendel S., Fornaro M., De Luca G., Orsolini G., Rossini M., Dieude P., Knitza J., Castaneda S., Voll R. E., Rojas-Serrano J., Valentini A., Vancheri C., Matucci-Cerinic M., Feist E., Codullo V., Iannone F., Distler J. H., Montecucco C., Gonzalez-Gay M. A., Cavagna, L, Meloni, F, Meyer, A, Sambataro, G, Belliato, M, De Langhe, E, Cavazzana, I, Pipitone, N, Triantafyllias, K, Mosca, M, Barsotti, S, Zampogna, G, Biglia, A, Emmi, G, De Visser, M, Van Der Kooi, A, Parronchi, P, Hirschi, S, da Silva, J, Scire, C, Furini, F, Giannini, M, Martinez Gonzalez, O, Damian, L, Piette, Y, Smith, V, Mera-Valera, A, Bachiller-Corral, J, Cabezas Rodriguez, I, Brandy-Garcia, A, Maurier, F, Perrin, J, Gonzalez-Moreno, J, Drott, U, Delbruck, C, Schwarting, A, Arrigoni, E, Sebastiani, G, Iuliano, A, Nannini, C, Quartuccio, L, Rodriguez Cambron, A, Blazquez Canamero, M, Villa Blanco, I, Cagnotto, G, Pesci, A, Luppi, F, Dei, G, Romero Bueno, F, Franceschini, F, Chiapparoli, I, Zanframundo, G, Lettieri, S, De Stefano, L, Cutolo, M, Mathieu, A, Piga, M, Prieto-Gonzalez, S, Moraes-Fontes, M, Fonseca, J, Jovani, V, Riccieri, V, Santaniello, A, Montfort, S, Bilocca, D, Erre, G, Bartoloni, E, Gerli, R, Monti, M, Lorenz, H, Sambataro, D, Bellando Randone, S, Schneider, U, Valenzuela, C, Lopez-Mejias, R, Cifrian, J, Mejia, M, Gonzalez Perez, M, Wendel, S, Fornaro, M, De Luca, G, Orsolini, G, Rossini, M, Dieude, P, Knitza, J, Castaneda, S, Voll, R, Rojas-Serrano, J, Valentini, A, Vancheri, C, Matucci-Cerinic, M, Feist, E, Codullo, V, Iannone, F, Distler, J, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Meloni F., Meyer A., Sambataro G., Belliato M., De Langhe E., Cavazzana I., Pipitone N., Triantafyllias K., Mosca M., Barsotti S., Zampogna G., Biglia A., Emmi G., De Visser M., Van Der Kooi A., Parronchi P., Hirschi S., da Silva J. A. P., Scire C. A., Furini F., Giannini M., Martinez Gonzalez O., Damian L., Piette Y., Smith V., Mera-Valera A., Bachiller-Corral J., Cabezas Rodriguez I., Brandy-Garcia A. M., Maurier F., Perrin J., Gonzalez-Moreno J., Drott U., Delbruck C., Schwarting A., Arrigoni E., Sebastiani G. D., Iuliano A., Nannini C., Quartuccio L., Rodriguez Cambron A. B., Blazquez Canamero M. A., Villa Blanco I., Cagnotto G., Pesci A., Luppi F., Dei G., Romero Bueno F. I., Franceschini F., Chiapparoli I., Zanframundo G., Lettieri S., De Stefano L., Cutolo M., Mathieu A., Piga M., Prieto-Gonzalez S., Moraes-Fontes M. F., Fonseca J. E., Jovani V., Riccieri V., Santaniello A., Montfort S., Bilocca D., Erre G. L., Bartoloni E., Gerli R., Monti M. C., Lorenz H. M., Sambataro D., Bellando Randone S., Schneider U., Valenzuela C., Lopez-Mejias R., Cifrian J., Mejia M., Gonzalez Perez M. -I., Wendel S., Fornaro M., De Luca G., Orsolini G., Rossini M., Dieude P., Knitza J., Castaneda S., Voll R. E., Rojas-Serrano J., Valentini A., Vancheri C., Matucci-Cerinic M., Feist E., Codullo V., Iannone F., Distler J. H., Montecucco C., and Gonzalez-Gay M. A.
- Abstract
Objective To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies. Methods We conducted a multicentre, international, retrospective cohort study. Results 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included. Dermatomyositis (64, 43%) and amyopathic dermatomyositis (47, 31%), were the main diagnosis; 15 patients (10%) were classified as interstitial pneumonia with autoimmune features (IPAF) and 7 (5%) as rheumatoid arthritis. The main clinical findings observed were myositis (84, 56%), interstitial lung disease (ILD) (108, 78%), skin lesions (111, 74%), and arthritis (76, 51%). The onset of these manifestations was not concomitant in 74 cases (50%). Of note, 32 (21.5%) patients were admitted to the intensive care unit for rapidly progressive-ILD, which occurred in median 2 months from lung involvement detection, in the majority of cases (28, 19%) despite previous immunosuppressive treatment. One-third of patients (47, 32% each) was ANA and anti-ENA antibodies negative and a similar percentage was anti-Ro52 kDa antibodies positive. Non-specific interstitial pneumonia (65, 60%), organising pneumonia (23, 21%), and usual interstitial pneumonia-like pattern (14, 13%) were the main ILD patterns observed. Twenty-six patients died (17%), 19 (13%) had a rapidly progressive-ILD. Conclusion The clinical spectrum of the anti-MDA5 antibodies-related disease is heterogeneous. Rapidly-progressive ILD deeply impacts the prognosis also in non-Asian patients, occurring early during the disease course. Anti-MDA5 antibody positivity should be considered even when baseline autoimmune screening is negative, anti-Ro52 kDa antibodies are positive, and radiology findings show a NSIP pattern.
- Published
- 2022
32. Diagnosis and management of urinary tract infections in children aged 2 months to 3 years in the Italian emergency units: the ItaUTI study
- Author
-
Cenzato, F, Milani, G, Amigoni, A, Sperotto, F, Bianchetti, M, Agostoni, C, Montini, G, Farello, G, Chiarelli, F, Greco, R, Di Lollo, F, Rocco Forte, F, Manieri, S, Carpino, L, Caloiero, M, Cirisano, A, Bragho, S, Della Casa, R, Nunziata, F, Pecoraro, C, Pacifico, R, Lanari, M, Ghizzi, C, Serra, L, Stella, M, Maggiore, G, Fiorini, R, Dodi, I, Morelli, A, Lughetti, L, Cella, A, Vergine, G, De Fanti, A, Dragovic, D, Santori, D, Cozzi, G, Cogo, P, Raponi, M, Lubrano, R, de Martinis, M, Gatto, A, Barbieri, M, Reale, A, Bracaglia, G, Piccotti, E, Borea, R, Gaiero, A, Martelli, L, Arrighini, A, Cianci, P, Cavalli, C, De Santis, L, Pietra, B, Biondi, A, Sala, M, Pogliani, L, Cherubini, S, Bellini, M, Bruni, P, Traina, G, Tommasi, P, Del Barba, P, Arrigoni, S, Salvini, F, Bernardo, L, Bertolozzi, G, Fasoli, S, Marseglia, G, Palumbo, E, Bosco, A, Mirri, G, Fabiani, E, Ruffini, E, Pieragostini, L, Fornaro, M, Ripanti, G, Pannoni, D, Enrico, F, Perona, A, Tappi, E, Nis Haitink, O, Rabbone, I, Capalbo, P, Urbino, A, Guala, A, Cosi, G, Barracchia, M, Martire, B, Cardinale, F, Moramarco, F, Perrone, C, Campanozzi, A, Cecinati, V, Canetto, A, Clemente, C, Cualbu, A, Narducci, F, Mula, G, Bulciolu, P, Antonucci, R, Gramaglia, G, Cavaleri, G, Salpietro, C, Corsello, G, Salvo, R, Palmeri, M, Vitale, M, Morgano, A, Falorni, S, Peroni, D, Masi, S, Bertini, A, Vaccaro, A, Vasarri, P, Reinstadler, P, Soffiati, M, Stefanelli, M, Verrotti di Pianella, A, Bertone, C, Marzini, S, Da Dalt, L, Rugolotto, S, Scozzola, F, Ecclesio Livio, L, Cinquetti, M, Silvagni, D, Bellettato, M, Cenzato F., Milani G. P., Amigoni A., Sperotto F., Bianchetti M. G., Agostoni C., Montini G., Farello G., Chiarelli F., Greco R., Di Lollo F., Rocco Forte F., Manieri S., Carpino L., Caloiero M., Cirisano A., Bragho S., Della Casa R., Nunziata F., Pecoraro C., Pacifico R., Lanari M., Ghizzi C., Serra L., Stella M., Maggiore G., Fiorini R., Dodi I., Morelli A., Lughetti L., Cella A., Vergine G., De Fanti A., Dragovic D., Santori D., Cozzi G., Cogo P., Raponi M., Lubrano R., de Martinis M., Gatto A., Barbieri M. A., Reale A., Bracaglia G., Piccotti E., Borea R., Gaiero A., Martelli L., Arrighini A., Cianci P., Cavalli C., De Santis L., Pietra B. C., Biondi A., Sala M., Pogliani L. M., Cherubini S., Bellini M., Bruni P., Traina G., Tommasi P., Del Barba P., Arrigoni S., Salvini F. M., Bernardo L., Bertolozzi G., Fasoli S., Marseglia G. L., Palumbo E., Bosco A., Mirri G., Fabiani E., Ruffini E., Pieragostini L., Fornaro M., Ripanti G., Pannoni D., Enrico F., Perona A., Tappi E., Nis Haitink O., Rabbone I., Capalbo P. T., Urbino A., Guala A., Cosi G., Barracchia M. G., Martire B., Cardinale F., Moramarco F., Perrone C., Campanozzi A., Cecinati V., Canetto A., Clemente C., Cualbu A., Narducci F., Mula G., Bulciolu P., Antonucci R., Gramaglia G., Cavaleri G., Salpietro C., Corsello G., Salvo R., Palmeri M., Vitale M. A., Morgano A., Falorni S., Peroni D., Masi S., Bertini A., Vaccaro A., Vasarri P., Reinstadler P., Soffiati M., Stefanelli M., Verrotti di Pianella A., Bertone C., Marzini S., Da Dalt L., Rugolotto S., Scozzola F., Ecclesio Livio L., Cinquetti M., Silvagni D., Bellettato M., Cenzato, F, Milani, G, Amigoni, A, Sperotto, F, Bianchetti, M, Agostoni, C, Montini, G, Farello, G, Chiarelli, F, Greco, R, Di Lollo, F, Rocco Forte, F, Manieri, S, Carpino, L, Caloiero, M, Cirisano, A, Bragho, S, Della Casa, R, Nunziata, F, Pecoraro, C, Pacifico, R, Lanari, M, Ghizzi, C, Serra, L, Stella, M, Maggiore, G, Fiorini, R, Dodi, I, Morelli, A, Lughetti, L, Cella, A, Vergine, G, De Fanti, A, Dragovic, D, Santori, D, Cozzi, G, Cogo, P, Raponi, M, Lubrano, R, de Martinis, M, Gatto, A, Barbieri, M, Reale, A, Bracaglia, G, Piccotti, E, Borea, R, Gaiero, A, Martelli, L, Arrighini, A, Cianci, P, Cavalli, C, De Santis, L, Pietra, B, Biondi, A, Sala, M, Pogliani, L, Cherubini, S, Bellini, M, Bruni, P, Traina, G, Tommasi, P, Del Barba, P, Arrigoni, S, Salvini, F, Bernardo, L, Bertolozzi, G, Fasoli, S, Marseglia, G, Palumbo, E, Bosco, A, Mirri, G, Fabiani, E, Ruffini, E, Pieragostini, L, Fornaro, M, Ripanti, G, Pannoni, D, Enrico, F, Perona, A, Tappi, E, Nis Haitink, O, Rabbone, I, Capalbo, P, Urbino, A, Guala, A, Cosi, G, Barracchia, M, Martire, B, Cardinale, F, Moramarco, F, Perrone, C, Campanozzi, A, Cecinati, V, Canetto, A, Clemente, C, Cualbu, A, Narducci, F, Mula, G, Bulciolu, P, Antonucci, R, Gramaglia, G, Cavaleri, G, Salpietro, C, Corsello, G, Salvo, R, Palmeri, M, Vitale, M, Morgano, A, Falorni, S, Peroni, D, Masi, S, Bertini, A, Vaccaro, A, Vasarri, P, Reinstadler, P, Soffiati, M, Stefanelli, M, Verrotti di Pianella, A, Bertone, C, Marzini, S, Da Dalt, L, Rugolotto, S, Scozzola, F, Ecclesio Livio, L, Cinquetti, M, Silvagni, D, Bellettato, M, Cenzato F., Milani G. P., Amigoni A., Sperotto F., Bianchetti M. G., Agostoni C., Montini G., Farello G., Chiarelli F., Greco R., Di Lollo F., Rocco Forte F., Manieri S., Carpino L., Caloiero M., Cirisano A., Bragho S., Della Casa R., Nunziata F., Pecoraro C., Pacifico R., Lanari M., Ghizzi C., Serra L., Stella M., Maggiore G., Fiorini R., Dodi I., Morelli A., Lughetti L., Cella A., Vergine G., De Fanti A., Dragovic D., Santori D., Cozzi G., Cogo P., Raponi M., Lubrano R., de Martinis M., Gatto A., Barbieri M. A., Reale A., Bracaglia G., Piccotti E., Borea R., Gaiero A., Martelli L., Arrighini A., Cianci P., Cavalli C., De Santis L., Pietra B. C., Biondi A., Sala M., Pogliani L. M., Cherubini S., Bellini M., Bruni P., Traina G., Tommasi P., Del Barba P., Arrigoni S., Salvini F. M., Bernardo L., Bertolozzi G., Fasoli S., Marseglia G. L., Palumbo E., Bosco A., Mirri G., Fabiani E., Ruffini E., Pieragostini L., Fornaro M., Ripanti G., Pannoni D., Enrico F., Perona A., Tappi E., Nis Haitink O., Rabbone I., Capalbo P. T., Urbino A., Guala A., Cosi G., Barracchia M. G., Martire B., Cardinale F., Moramarco F., Perrone C., Campanozzi A., Cecinati V., Canetto A., Clemente C., Cualbu A., Narducci F., Mula G., Bulciolu P., Antonucci R., Gramaglia G., Cavaleri G., Salpietro C., Corsello G., Salvo R., Palmeri M., Vitale M. A., Morgano A., Falorni S., Peroni D., Masi S., Bertini A., Vaccaro A., Vasarri P., Reinstadler P., Soffiati M., Stefanelli M., Verrotti di Pianella A., Bertone C., Marzini S., Da Dalt L., Rugolotto S., Scozzola F., Ecclesio Livio L., Cinquetti M., Silvagni D., and Bellettato M.
- Abstract
Urinary tract infections (UTIs) are among the most frequent bacterial diseases in infants and children. Physician adherence to recommendations is notoriously often poor, but no data are available on UTIs management in the emergency setting. In this multicenter national study, we investigated the policies regarding UTIs management in children aged 2 months to 3 years in Italian emergency units. Between April and June 2021, directors of the emergency units were invited to answer an online survey on the following items: diagnostic approach to children with fever without an apparent source, therapeutic approach to UTIs, the use of kidney and urinary tract ultrasound, and the criteria for hospitalization. A total of 121 (89%) out of 139 of invited units participated in the study. Overall, units manage children with a suspected or confirmed UTI according to available recommendations for most of the items. However, in almost 80% (n = 94) of units, a sterile perineal bag is used to collect urine for culture. When urine is collected by cathether, heterogeneity exists on the threshold of bacterial load considered for UTI diagnosis. Conclusions: Available recommendations on UTIs in children are followed by Italian emergency units for most of the items. However, the methods to collect urine specimens for culture, one of the crucial steps of the diagnostic work-up, often do not align with current recommendations and CFU thresholds considered for diagnosis largely vary among centers. Efforts should be addressed to validate and implement new child and family friendly urine collection techniques.What is Known:• Several guidelines are published on the management of children with suspected or confirmed urinary tract infection.• No data are available on the management of pediatric urinary tract infections in the emergency setting.What is New:• Almost 80% of the Italian emergency units employ a sterile perineal bag to collect urine for culture.• Diagnostic
- Published
- 2022
33. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- Author
-
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, and Carvalho AF
- Subjects
antipsychotics ,side effects ,tolerability ,safety ,psychosis ,psychiatry ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Marco Solmi,1,2 Andrea Murru,3 Isabella Pacchiarotti,3 Juan Undurraga,4,5 Nicola Veronese,2,6 Michele Fornaro,7,8 Brendon Stubbs,2,9–11 Francesco Monaco,2 Eduard Vieta,3 Mary V Seeman,12 Christoph U Correll,13,14 André F Carvalho2,15 1Neuroscience Department, University of Padua, 2Institute for Clinical Research and Education in Medicine, Padua, Italy; 3Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; 4Department of Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo, 5Early Intervention Program, J. Horwitz Psychiatric Institute, Santiago, Chile; 6National Research Council, Ageing Section, Padua, 7Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, School of Medicine, University “Federico II”, Naples, Italy; 8New York State Psychiatric Institute, Columbia University, New York, NY, USA; 9Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 10Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, 11Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK; 12Institute of Medical Science, Toronto, ON, Canada; 13Department of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, 14Department of Psychiatry and Molecular Medicine Hempstead, Hofstra Northwell School of Medicine, Hempstead, NY, USA; 15Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil Abstract: Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients – psychosocial functioning, quality of life, and recovery. These drugs are no longer limited to specific Diagnostic and Statistical Manual of Mental Disorders (DSM) categories. Evidence indicates that SGAs show an improved safety and tolerability profile compared with FGAs. The incidence of treatment-emergent extrapyramidal side effects is lower, and there is less impairment of cognitive function and treatment-related negative symptoms. However, treatment with SGAs has been associated with a wide range of untoward effects, among which treatment-emergent weight gain and metabolic abnormalities are of notable concern. The present clinical review aims to summarize the safety and tolerability profile of selected FGAs and SGAs and to link treatment-related adverse effects to the pharmacodynamic profile of each drug. Evidence, predominantly derived from systematic reviews, meta-analyses, and clinical trials of the drugs amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, CPZ, haloperidol, loxapine, and perphenazine, is summarized. In addition, the safety and tolerability profiles of antipsychotics are discussed in the context of the “behavioral toxicity” conceptual framework, which considers the longitudinal course and the clinical and therapeutic consequences of treatment-emergent side effects. In SMI, SGAs with safer metabolic profiles should ideally be prescribed first. However, alongside with safety, efficacy should also be considered on a patient-tailored basis. Keywords: antipsychotics, side effects, tolerability, safety, psychosis, psychiatry
- Published
- 2017
34. Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
- Author
-
Rossano, F., Caiazza, C., Sobrino, A., Solini, N., Vellucci, A., Zotti, N., Fornaro, M., Gillman, K., Cattaneo, C.I., Eynde, V. Van den, Birkenhager, T.K., Ruhé, H.G., Stahl, S., Iasevoli, F., Bartolomeis, A. de, Rossano, F., Caiazza, C., Sobrino, A., Solini, N., Vellucci, A., Zotti, N., Fornaro, M., Gillman, K., Cattaneo, C.I., Eynde, V. Van den, Birkenhager, T.K., Ruhé, H.G., Stahl, S., Iasevoli, F., and Bartolomeis, A. de
- Abstract
01 juli 2023, Item does not contain fulltext, Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. The present systematic review and meta-analysis appraises the evidence of different formulations/dosages of selegiline across different psychiatric conditions. We inquired PubMed/MEDLINE/Cochrane-Central/WHO-ICTRP/Clarivate-WebOfScience and the Chinese-Electronic-Journal Database from inception to 10/26/2022 for selegiline trials involving psychiatric patients. Random-effects meta-analyses assessed heterogeneity, publication/risk biases, and confidence in the evidence, followed by sensitivity, subgroup, and meta-regression analyses. Co-primary outcomes were: changes in symptom score (standardized mean difference=SMD) and author-defined response (risk ratios=RRs). RRs of adverse events and all-cause discontinuation were secondary and acceptability outcomes, respectively. Systematic-review included 42 studies; meta-analysis, 23. Selegiline outperformed placebo in depressive symptom reduction (SMD=-0.96, 95%C.I.=-1.78, -0.14, k = 10, n = 1,308), depression (RR=1.61, 95%C.I.=1.20, 2.15, k = 9, n = 1,238) and atypical-depression response (RR=2.23, 95%C.I.=1.35, 3.68, k = 3, n = 136). Selegiline failed to outperform the placebo in negative (k = 4) or positive symptoms of schizophrenia (k = 4), attention-deficit-hyperactivity disorder (ADHD) symptoms reduction (k = 2), and smoking abstinence rate (k = 4). Selegiline did not differ from methylphenidate and ADHD scores (k = 2). No significant difference emerged in acceptability, incident diarrhea, headache, dizziness, and nausea RRs, in contrast to xerostomia (RR=1.58, 95%C.I. =1.03, 2.43, k = 6, n = 1,134), insomnia (RR=1.61, 95%C.I.=1.19, 2.17, k = 10, n = 1,768), and application-site reaction for transdermal formulation (RR=1.81, 95%C.I.=1.40, 2.33, k = 6, n = 1,662). Confidence in fin
- Published
- 2023
35. Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta-analysis.
- Author
-
Oliva, V., Prisco, M. De, Fico, G., Possidente, C., Fortea, L., Montejo, L., Anmella, G., Hidalgo-Mazzei, D., Grande, I., Murru, A., Fornaro, M., Bartolomeis, A. de, Dodd, A., Fanelli, G., Fabbri, C., Serretti, A., Vieta, E., Radua, J., Oliva, V., Prisco, M. De, Fico, G., Possidente, C., Fortea, L., Montejo, L., Anmella, G., Hidalgo-Mazzei, D., Grande, I., Murru, A., Fornaro, M., Bartolomeis, A. de, Dodd, A., Fanelli, G., Fabbri, C., Serretti, A., Vieta, E., and Radua, J.
- Abstract
Contains fulltext : 299975.pdf (Publisher’s version ) (Open Access), BACKGROUND: Emotion dysregulation (ED) is a transdiagnostic construct characterized by difficulties regulating intense emotions. People with bipolar disorder (BD) are more likely to show ED and use maladaptive emotion regulation strategies than adaptive ones. However, little is known about whether ED in BD is a trait or it is rather an epiphenomenon of mood symptoms. METHODS: We conducted a systematic review and meta-analysis of the evidence across major literature databases reporting correlations between measures of emotion regulation (overall ED and different emotion regulation strategies) and measures of depressive and (hypo)manic symptoms in BD from inception until April 12th, 2022. RESULTS: Fourteen studies involving 1371 individuals with BD were included in the qualitative synthesis, of which 11 reported quantitative information and were included in the meta-analysis. ED and maladaptive strategies were significantly higher during periods with more severe mood symptoms, especially depressive ones, while adaptive strategies were lower. CONCLUSION: ED significantly correlates with BD symptomatology, and it mainly occurs during mood alterations. ED may be a target for specific psychotherapeutic and pharmacological treatments, according to precision psychiatry. However, further studies are needed, including patients with mood episodes and longitudinal design, to provide more robust evidence and explore the causal direction of the associations., 01 december 2023
- Published
- 2023
36. Physical pain-suicidality association among all ages: updated meta-analyses
- Author
-
Calati, R, Rignanese, M, Salmè, E, Madeddu, F, De Prisco, M, Fornaro, M, Calati, R, Rignanese, M, Salmè, E, Madeddu, F, De Prisco, M, and Fornaro, M
- Published
- 2023
37. MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES : DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY)
- Author
-
Fornaro, M., Venerito, V., Iannone, F., Ravichandran, N., Nikiphorou, E., Joshi, M., Tan, A. L., Saha, S., Shinjo, S. Katsuyuki, Agarwal, V., Ziade, N., Velikova, T., Jagtap, K., Milchert, M., Parodis, Ioannis, Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Dzifa, D., Toro Gutierrez, C. E., Vinicio Caballero, C., Distler, O., Day, J., Chinoy, H., Aggarwal, R., Gupta, L., Fornaro, M., Venerito, V., Iannone, F., Ravichandran, N., Nikiphorou, E., Joshi, M., Tan, A. L., Saha, S., Shinjo, S. Katsuyuki, Agarwal, V., Ziade, N., Velikova, T., Jagtap, K., Milchert, M., Parodis, Ioannis, Gracia-Ramos, A. E., Cavagna, L., Kuwana, M., Knitza, J., Makol, A., Dzifa, D., Toro Gutierrez, C. E., Vinicio Caballero, C., Distler, O., Day, J., Chinoy, H., Aggarwal, R., and Gupta, L.
- Abstract
Background: Prevalence of comorbidities and their impact on health outcomes in Idiopathic inflammatory myopathies (IIMs) is limited. Objectives: This study aimed to explore the prevalence of multimorbidity in patients with IIMs, other autoimmune rheumatic diseases (AIRDs) and Healthy controls (HCs). We further explore the impact of comorbidities on patients’ physical, mental, and social health assessed by the Patient-Reported Outcome Measurement Information System (PROMIS instruments). Methods: Data for this study were acquired from the COVAD 2 e-survey hosted by a study group consisting of 167 collaborators in 110 countries. Basic multimorbidity (BM) was defined as the co-occurrence of two or more comorbidities in an individual, while complex multimorbidity (CM) signified the co-occurrence of 3 or more chronic conditions affecting 3 or more different organ systems. PROMIS global physical health (PGP), mental health (PGM), fatigue 4a (F4a) and physical function short form (SF10) were analysed using descriptive statistics and linear regression models. Hierarchical Clustering on Principal Components was performed to outline the grouping. Results: Of 10740 complete respondents, 1558 IIMs, 4591 AIRDs and 3652 HCs were analysed. Individuals with IIMs exhibited high burden of any comorbidity (OR: 1.62 vs AIRDs and 2.95 vs HCs,p<0.01), BM (OR 1.66 vs AIRDs and 3.52 vs HCs,p<0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs,p<0.01), and mental health disorders (MHDs) (OR 1.33 vs AIRDs and 2.63 vs HCs,p<0.01). IIM patients with comorbidities (and MHDs) had worse physical function (low PGP, PGM, SF10 and higher F4a scores, all p<0.001). Worse physical function (PGP) was predicted by age (0.35; 0.030), active disease (-1.51; <0.001), BM (-1.11; <0.001), and MHDs (-1.47; <0.001). PGM was impacted by age (0.51; 0.004), active disease (-1.34, <0.001), BM (-0.75; 0.001) and MHDs (-2.22; <0.001). Determinants of SF10a were age (-3.86; <0.001), active dis
- Published
- 2023
- Full Text
- View/download PDF
38. Suicide risk among residents and PhD students: A systematic review of the literature
- Author
-
Poli, M, Russotto, S, Fornaro, M, Gonda, X, Lopez-Castroman, J, Madeddu, F, Zeppegno, P, Gramaglia, C, Calati, R, Marianna Poli, Sophia Russotto, Michele Fornaro, Xenia Gonda, Jorge Lopez-Castroman, Fabio Madeddu, Patrizia Zeppegno, Carla Gramaglia, Raffaella Calati, Poli, M, Russotto, S, Fornaro, M, Gonda, X, Lopez-Castroman, J, Madeddu, F, Zeppegno, P, Gramaglia, C, Calati, R, Marianna Poli, Sophia Russotto, Michele Fornaro, Xenia Gonda, Jorge Lopez-Castroman, Fabio Madeddu, Patrizia Zeppegno, Carla Gramaglia, and Raffaella Calati
- Published
- 2023
39. Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients
- Author
-
Cacciapaglia, F., Airo, P., Fornaro, M., Trerotoli, Paolo, De Lorenzis, E., Corrado, A., Lazzaroni, M. G., Natalello, G., Montini, F., Altomare, Annamaria, Urso, L., Verardi, Lucrezia, Bosello, Silvia Laura, Cantatore, F. P., Iannone, F., Trerotoli P., Altomare A., Verardi L., Bosello S. L. (ORCID:0000-0002-4837-447X), Cacciapaglia, F., Airo, P., Fornaro, M., Trerotoli, Paolo, De Lorenzis, E., Corrado, A., Lazzaroni, M. G., Natalello, G., Montini, F., Altomare, Annamaria, Urso, L., Verardi, Lucrezia, Bosello, Silvia Laura, Cantatore, F. P., Iannone, F., Trerotoli P., Altomare A., Verardi L., and Bosello S. L. (ORCID:0000-0002-4837-447X)
- Abstract
Objectives: Survival and death prognostic factors of SSc patients varied during the past decades. We aimed to update the 5- and 10-year survival rates and identify prognostic factors in a multicentre cohort of Italian SSc patients diagnosed after 2009. Material and methods: Patients who received a diagnosis of SSc after 1 January 2009 and were longitudinally followed up in four Italian rheumatologic centres were retrospectively assessed up to 31 December 2020. Overall survival of SSc patients was described using the Kaplan–Meier method. Predictors of mortality at 10-year follow-up were assessed by the Cox regression model. A comparison of our cohort with the Italian general population was performed by determining the standardized mortality ratio (SMR). Results: A total of 912 patients (91.6% females, 20% dcSSc) were included. Overall survival rates at 5 and 10 years were 94.4% and 89.4%, respectively. The SMR was 0.96 (95% CI 0.81, 1.13), like that expected in the Italian general population. Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) associated with pulmonary hypertension (PH) significantly reduced survival (P < 0.0001). Main death predictors were male gender (HR 1⁄4 2.76), diffuse cutaneous involvement (HR 1⁄4 3.14), older age at diagnosis (HR 1⁄4 1.08), PAH (HR 1⁄4 3.21), ILD-associated PH (HR 1⁄4 4.11), comorbidities (HR 1⁄4 3.53) and glucocorticoid treatment (HR1⁄4 2.02). Conclusions: In the past decade, SSc patients have reached similar mortality of that expected in the Italian general population. Male gender, diffuse cutaneous involvement, comorbidities and PAH with or without ILD represent the main poor prognostic factors.
- Published
- 2023
40. The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis
- Author
-
Fornaro, M., Orsolini, L., Marini, S., De Berardis, D., Perna, G., Valchera, A., Ganança, L., Solmi, M., Veronese, N., and Stubbs, B.
- Published
- 2016
- Full Text
- View/download PDF
41. Geotechnical features for quarrying abandoned underground marble voids: The Monte Altissimo example, Apuane Range
- Author
-
Fornaro, M., primary, Gennaro, R., additional, and Oggeri, C., additional
- Published
- 2018
- Full Text
- View/download PDF
42. What emotional regulation strategies are most related to the affective symptoms of bipolar disorder? A systematic review and network meta-analysis
- Author
-
Oliva, V., primary, De Prisco, M., additional, Fico, G., additional, Possidente, C., additional, Fortea, L., additional, Montejo, L., additional, Anmella, G., additional, Hidalgo-Mazzei, D., additional, Grande, I., additional, Murru, A., additional, Fornaro, M., additional, De Bartolomeis, A., additional, Fanelli, G., additional, Fabbri, C., additional, Serretti, A., additional, Vieta, E., additional, and Radua, J., additional
- Published
- 2023
- Full Text
- View/download PDF
43. How heterogeneous is emotion dysregulation in the general population? A preliminary meta-analysis
- Author
-
De Prisco, M., primary, Oliva, V., additional, Fico, G., additional, Fornaro, M., additional, De Bartolomeis, A., additional, Serretti, A., additional, Vieta, E., additional, and Murru, A., additional
- Published
- 2023
- Full Text
- View/download PDF
44. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials
- Author
-
Fornaro M, Solmi M, Perna G, De Berardis D, Veronese N, Orsolini L, Ganança L, and Stubbs B
- Subjects
Lisdexamfetamine ,binge eating disorder ,systematic-review ,meta-analysis. ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Michele Fornaro,1,2 Marco Solmi,3–5 Giampaolo Perna,2,6 Domenico De Berardis,2,7 Nicola Veronese,5,8 Laura Orsolini,2,9 Licinia Ganança,1,10 Brendon Stubbs11,12 1New York State Psychiatric Institute, Columbia University, New York City, NY, USA; 2Polyedra Research Group®, Ascoli, 3Department of Neurosciences, University of Padua, 4Department of Mental Health, National Health Service, Padova, 5IREM Institute for Clinical Research and Education in Medicine, Padova, 6Department of Clinical Neurosciences, Hermanas Hospitalarias – Villa San Benedetto Menni Hospital, FoRiPsi, Albese con Cassano, Como, 7Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, National Health Service, Hospital “G Mazzini”, Teramo, 8Department of Medicine (DIMED), University of Padua, Padova, Italy; 9Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK; 10Department of Psychiatry, School of Medicine, University of Lisbon, Lisbon, Portugal; 11Department of Health Service and Population Research, Institute of Psychiatry, King’s College London, 12Department of Physiotherapy, South London and Maudsley NHS Foundation Trust, London, UK Background: Preliminary placebo-controlled evidence paved the ground to the US Food and Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-to-severe binge eating disorder (BED) in adults.Objectives: To provide a preliminary qualitative and quantitative synthesis of the placebo-controlled, randomized clinical trials (RCTs) considering the efficacy and tolerability of lisdexamfetamine in the acute and/or maintenance treatment of moderate-to-severe BED in adults.Methods: A preliminary, yet comprehensive, systematic review was performed by accessing a broad range of resources providing publicly available data about lisdexamfetamine at the time of inquiry (March 2016). Study eligibility criteria, participants, and interventions were considered focusing on major clinical and functional outcomes of either efficacy or tolerability of lisdexamfetamine in the treatment of moderate-to-severe BED in adults.Results: Meta-analysis of data pooled from three acute RCTs significantly favored lisdexamfetamine over placebo in the reduction of binge eating days/week, Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating total score, weight, response, and remission rates (all, P≤0.01). In contrast, discontinuation rates due to treatment-emergent adverse events were significantly higher among patients in receipt of lisdexamfetamine (relative risk 2.19, P=0.04) versus placebo.Limitations: Publication, selection, performance, attrition, reporting, sponsorship, and “diagnostic shift” biases. Lack of inclusion of adverse event effects other than those requiring discontinuation of the trial(s), as well as lack of information about clinically relevant psychiatric or other medical comorbidities, limits the overall generalizability of pooled results.Conclusion: Across the included acute phase RCTs, lisdexamfetamine (at 30, 50, or 70 mg/day) led to significant reduction in a number of clinically relevant outcomes compared to placebo. Moreover, safety concerns related to adverse events, high discontinuation rates, and the need for additional long-term maintenance of RCTs solicit careful monitoring of the drug in terms of overall safety and tolerability by further RCTs. Keywords: lisdexamfetamine, binge eating disorder, systematic review, meta-analysis
- Published
- 2016
45. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
- Author
-
Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, and Stubbs B
- Subjects
Bipolar Disorder ,polypharmacy ,prevalence ,systematic review. ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Michele Fornaro,1 Domenico De Berardis,2 Ann Sarah Koshy,3 Giampaolo Perna,4 Alessandro Valchera,5 Davy Vancampfort,6 Brendon Stubbs7,8 1New York Psychiatric Institute, Columbia University, New York, NY, USA; 2National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, Teramo, Italy; 3St. John’s National Academy of Health Sciences, Bangalore, India; 4Department of Clinical Neurosciences, Hermanas Hospitalarias - Villa San Benedetto Menni Hospital, FoRiPsi, 5Hermanas Hospitalarias, FoRiPsi Villa S. Giuseppe Hospital, Ascoli Piceno, Italy; 6Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium; 7Physiotherapy Department, South London and Maudsley NHS Foundation Trust, 8Health Service and Population Research Department, Institute of Psychiatry, King’s College London, London, UK Background: Uncertainty exists regarding the prevalence and clinical features associated with the practice of polypharmacy in bipolar disorder (BD), warranting a systematic review on the matter.Methods: Three authors independently searched major electronic databases from inception till September 2015. Articles were included that reported either qualitative or quantitative data about the prevalence and clinical features associated with polypharmacy in adult cases of BD.Results: The operative definitions of polypharmacy adopted across varying studies varied, with concomitant use of two or more psychotropic medications or use of four or more psychotropic medications at once being the most common and the most reliable, respectively. Regardless of type or current mood episode polarity of BD, prevalence rates up to 85% and 36% were found using the most permissive (two or more medications at once) and the most conservative (four or more) operative definitions for polypharmacy, respectively. Point prevalence prescription rates of one or more antidepressant or antipsychotic as part of a polypharmacy regimen occurred in up to 45% or 80% of the cases, respectively, according to the most permissive definition of polypharmacy. In contrast, lithium prescription rates ranged from 13% to 33% in BD patients receiving polypharmacy according to conservative and permissive definitions, possibly suggesting a reduced need for augmentation of combination strategies for those cases of BD with a favorable lifetime lithium response and/or long-lasting treatment as well as less likelihood of lithium response over the time most severe cases possibly exposed to a more complex polypharmacy overall.Limitations: “Apples and oranges” bias; publication bias for most recently introduced compounds.Conclusion: Polypharmacy is common among people with BD across varying type and mood episode phases of illness. Special population, including BD patients at high risk of familial load for suicidal behavior, solicit further research as well as the plausible “protective” role of lithium toward polypharmacy in BD. The PROSPERO registration number is CRD42014015084. Keywords: bipolar disorder, polypharmacy, prevalence, systematic review
- Published
- 2016
46. Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
- Author
-
Sen, P, Naveen, R, Houshmand, N, Kia, Sm, Joshi, M, Saha, S, Jagtap, K, Agarwal, V, Nune, A, Nikiphorou, E, Tan, Al, Shinjo, Sk, Ziade, N, Velikova, T, Milchert, M, Parodis, I, Gracia-Ramos, Ae, Cavagna, L, Kuwana, M, Knitza, J, Makol, A, Patel, A, Pauling, Jd, Wincup, C, Barman, B, Tehozol, Eaz, Serrano, Jr, de la Torre, I, Colunga-Pedraza, Ij, Merayo-Chalico, J, Chibuzo, Oc, Katchamart, W, Goo, Pa, Shumnalieva, R, Chen, Ym, Hoff, Ls, El Kibbi, L, Halabi, H, Vaidya, B, Shaharir, Ss, Hasan, Atmt, Dey, D, Gutierrez, Cet, Caballero-Uribe, Cv, Lilleker, Jb, Salim, B, Gheita, T, Chatterjee, T, Distler, O, Saavedra, Ma, Day, J, Chinoy, H, COVAD Study Grp, Kardes, S, Kardes, Sa, Andreoli, L, Lini, D, Screiber, K, Vince, Mn, Singh, Yp, Ranjan, R, Jain, A, Pandya, Sc, Pilania, Rk, Sharma, A, Manoj, Mm, Gupta, V, Kavadichanda, Cg, Patro, Ps, Ajmani, S, Phatak, S, Goswami, Rp, Chowdhury, Ac, Mathew, Aj, Shenoy, P, Asranna, A, Bommakanti, Kt, Shukla, A, Pande, Ar, Chandwar, K, Ghodke, A, Boro, H, Fazal, Zz, Cansu, Du, Yildirim, R, Gasparyan, Ay, Del Papa, N, Sambataro, G, Fabiola, A, Govoni, M, Parisi, S, Bocci, Eb, Sebastiani, Gd, Fusaro, E, Sebastiani, M, Quartuccio, L, Franceschini, F, Sainaghi, Pp, Orsolini, G, De Angelis, R, Danielli, Mg, Venerito, V, Grignaschi, S, Giollo, A, Alluno, A, Ioannone, F, Fornaro, M, Traboco, Ls, Wibowo, Sak, Loarce-Martos, J, Prieto-Gonzalez, S, Gonzalez, Ra, Yoshida, A, Nakashima, R, Sato, S, Kimura, N, Kaneko, Y, Gono, T, Tomaras, S, Proft, Fn, Holzer, Mt, Gromova, Ma, Aharonov, O, Griger, Z, Hmamouchi, I, El Bouchti, I, Baba, Z, Giannini, M, Maurier, F, Campagne, J, Meyer, A, Langguth, D, Limaye, V, Needham, M, Srivastav, N, Hudson, M, Landon-Cardinal, O, Zuleta, Wgr, Arbelaez, A, Cajas, J, Silva, Jap, Fonseca, Je, Zimba, O, Bohdana, D, Ima-Edomwonyi, U, Dedeke, I, Airenakho, E, Madu, Nh, Yerima, A, Olaosebikan, H, Becky, A, Koussougbo, Od, Palalane, E, So, H, Ugarte-Gil, Mf, Chinchay, L, Bernaola, Jp, Pimentel, V, Fathi, Hm, Mohammed, Rha, Harifi, G, Fuentes-Silva, Y, Cabriza, K, Losanto, J, Colaman, N, Cachafeiro-Vilar, A, Bautista, Gg, Ejg, Ho, Gonzalez, R, Nunez, Ls, Vergara, Mc, Baez, Jt, Alonzo, H, Pastelin, Cbs, Salinas, Rg, Obiols, Aq, Chavez, N, Ordonez, Ab, Argueta, S, Llerena, Gar, Sierra-Zorita, R, Arrieta, D, Hidalgo, Er, Saenz, R, Escalante, Mi, Morales, R, Calapaqui, W, Quezada, I, Arredondo, G, Aggarwal, R, and Gupta, L
- Subjects
Rheumatology ,idiopathic inflammatory myopathies ,COVID-19 vaccines ,vaccine hesitancy ,registries ,Pharmacology (medical) ,autoimmune disease - Abstract
ObjectiveCOVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys.MethodsThe first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups.ResultsWe analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P ConclusionVaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
- Published
- 2023
47. Incidenza di suicidio ed omicidio nel periodo precedente e concomitante al COVID-19: stratificazione per genere ed età e confronto con altri paesi
- Author
-
Calati, R, Gentile, G, Fornaro, M, Madeddu, F, Tambuzzi, S, Zoja, R, Calati R, Gentile G, Fornaro M, Madeddu F, Tambuzzi S, Zoja R, Calati, R, Gentile, G, Fornaro, M, Madeddu, F, Tambuzzi, S, Zoja, R, Calati R, Gentile G, Fornaro M, Madeddu F, Tambuzzi S, and Zoja R
- Published
- 2021
48. Cancer diagnosis and suicide outcomes: Umbrella review and methodological considerations
- Author
-
Calati, R, Filipponi, C, Mansi, W, Casu, D, Peviani, G, Gentile, G, Tambuzzi, S, Zoja, R, Fornaro, M, Lopez-Castroman, J, Madeddu, F, Calati R., Filipponi C., Mansi W., Casu D., Peviani G., Gentile G., Tambuzzi S., Zoja R., Fornaro M., Lopez-Castroman J., Madeddu F., Calati, R, Filipponi, C, Mansi, W, Casu, D, Peviani, G, Gentile, G, Tambuzzi, S, Zoja, R, Fornaro, M, Lopez-Castroman, J, Madeddu, F, Calati R., Filipponi C., Mansi W., Casu D., Peviani G., Gentile G., Tambuzzi S., Zoja R., Fornaro M., Lopez-Castroman J., and Madeddu F.
- Abstract
Background: Suicide outcomes in cancer patients represent a major public health concern. We performed an umbrella review (UR) including all meta-analyses (MAs) and systematic reviews (SRs) published on the association between cancer and suicide outcomes. Methods: Eligible studies were searched in the main scientific databases up to January 23rd, 2021. Eligible MAs/SRs focused on all suicide phenotypes among cancer patients. Evidence of the association was extracted; the credibility and quality of the included studies were evaluated using ad-hoc tools, including “A MeaSurement Tool to Assess systematic Reviews-2-Revised” (AMSTAR-2-R). Results: Six MAs and 6 SRs were included. The standardized mortality ratio of suicide in cancer patients was 1.5 to 1.7-fold higher than in the general population. Risk factors for suicide outcomes among cancer patients were male sex and older age, a cancer diagnosis within the prior year, and some specific cancer sites. Among 107 associations, 90 (84.1%) were supported by high credibility of evidence (class II). However, all studies reported a large heterogeneity (I2> 50%) and the majority of them reported considerable heterogeneity (I2> 75%). All MAs used random-effects measures. All MAs but one assessed publication bias and only one disclosed it. The majority of MAs/SRs showed critically low quality based on AMSTAR-2-R. Limitations: We could not perform additional analyses due to the limited number of MAs. Conclusions: This UR underlines the inflated risk for suicide among cancer patients. Upcoming, well-designed studies are needed to account for a broader set of variables. Several methodological issues likewise warrant attention.
- Published
- 2021
49. Preliminary suicide trends during the COVID-19 pandemic in Milan, Italy
- Author
-
Calati, R, Gentile, G, Fornaro, M, Tambuzzi, S, Zoja, R, Calati R., Gentile G., Fornaro M., Tambuzzi S., Zoja R., Calati, R, Gentile, G, Fornaro, M, Tambuzzi, S, Zoja, R, Calati R., Gentile G., Fornaro M., Tambuzzi S., and Zoja R.
- Abstract
Europe was the second most affected continent by the 2019 coronavirus disease (COVID-19) pandemic, with Italy paying very high death tolls, especially in Lombardy, a region in Northern Italy. The pandemic profoundly impacted mental health and the world's rates of suicide since its outbreak. COVID-19-related suicide rates nonetheless followed a non-linear trend over the pandemic, decreasing after the COVID-19 outbreak, then raising during an extended follow-up period. Thus, we aimed to further assess the suicide rates in Lombardy. We carried out a retrospective analysis of all the autopsies performed in the year 2020 and within the first four months of the year 2021 through the database of the Institute of Forensic Medicine in Milan. In the year 2020, the recorded suicides decreased in comparison to 2016-2019 (21.19-22.97% of the autopsies), being 98 (18.08% out of 542 autopsies), while, in the first 4 months of the year 2021, 35 suicides were documented (185 autopsies, overall). Since the region of Lombardy was severely affected by COVID-19 since the early months of the year 2020, the extended retrospective follow-up allowed for firmer conclusions and insights about the need to extend the follow-up of COVID-19 pandemic beyond the first months after the outbreak, worldwide. This is with special emphasis towards the need to allocate the proper funds for mental health prevention for the general population as well as the most vulnerable ones, such as people with severe mental illness and caregivers, frontline health workers, and others bereaved by COVID-19.
- Published
- 2021
50. Cancer diagnosis and suicide outcomes: prevalence and risk meta-analysis
- Author
-
Peviani G, Casu D, Mansi W, De Prisco M, Madeddu F, López-Castroman J, Fornaro M, Calati R, Peviani, G, Casu, D, Mansi, W, De Prisco, M, Madeddu, F, López-Castroman, J, Fornaro, M, and Calati, R
- Subjects
Psychiatry and Mental health ,Cancer, suicide, meta-analysis - Abstract
Introduction Available meta-analytic evidence suggests an increased risk of suicide among cancer patients, although most of the reports focused on the sole suicide death (SD) outcome and they are usually hampered by significant between-study heterogeneity. Objectives The present meta-analysis aimed at assessing the prevalence and risk rates of SD, suicide attempt (SA), and suicidal ideation (SI) among cancer patients. Methods Systematic search up to April 2021 of observational studies documenting cancer and suicide outcomes associations. Pooled prevalence estimates, odd ratios (ORs), risk ratios (RRs), and hazard ratios (HRs) of SD, SA, and SI were computed according to the random-effects model. SD prevalence underwent cumulative and sub-group analyses for different variables. Risk estimates underwent sensitivity analysis for study design. Results Overall, thirty-nine studies were included. A higher risk of SD based on HR, SA based on OR and HR, and SI based on each measure was recorded among cancer patients versus controls. OR and RR of SD were not significant. Pooled prevalence rates of SD, SA and SI among cancer patients were 1.9% (1.1-3.1%), 1.4% (0.3-7.1%), and 9.1% (5.8-14.0%), respectively. Although high between-study heterogeneity held upon sensitivity and sub-group analyses, the overall message brought by risk analyses likewise held true. Age, country, study design, cancer type, sample size, cases type and comparison affected SD prevalence estimates in cancer patients. SD prevalence decreased over time. Conclusions Cancer patients face higher risk for SA and SI versus controls. SD’ results were controversial. Cancer patients have higher prevalence rates of suicide outcomes compared to the general population. Disclosure No significant relationships.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.